This year, the Food and Drug Administration announced it was taking steps to help gene therapies gain accelerated approval. Throughout 2022, the FDA approved three new gene therapy treatments for adult patients with various health issues including bladder cancer, Hemophilia B and more.
In April, scientists at Trinity College Dublin announced a significant development towards a new therapeutic treatment of glaucoma.
As scientists continue to make strides in gene therapy to provide new treatments and companies evaluate these health care options, consumers are fearing exorbitantly high costs, and insurers are left with questions on how this impacts plans and policies.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
